(March 6, 2024, 12:33 PM EST) -- WASHINGTON, D.C. — In a review of five inter partes reviews (IPRs) by the Patent Trial and Appeal Board of patented pneumococcal vaccine technology, the Federal Circuit U.S. Court of Appeals ruled March 5 that although the board correctly deemed 45 claims obvious to a person of skill in the art (POSITA) and properly denied a bid by Pfizer Inc. to add five substitute claims, it must revisit its denial of two other newly proposed claims....